Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma

Inclusion Criteria: * Over 19 years * Diagnosis of HCC * Unresectable asymtomatic uninodular or multinodular tumor. * Subject who maintain clinically normal hepatopetal flow without main portal vein closure * At least one measurable target lesion by CT or MRI which 10 mm or more and 100 mm or less. * ECOG Performance Status of 0 or 1. * Child-Pugh class A or B * Life expectancy of at least 6 months. Exclusion Criteria: * Another primary tumour, with the exception of conventional basal cell carcinoma or superficial bladder neoplasia * Hepatic resection, liver transplantation or Percutaneous local treatment * Previously received HCC related medical procedure * Previously treated with anthracyclines * Only measurable disease is within an area of the liver previously subjected to radiotherapy. * Child Pugh C * Active gastrointestinal bleeding within 6 months from screening. * Total bilirubin \> 3mg/dL * WBC \< 3,000cells/mm3 * Platelet \< 50,000mm3 * Serum creatinine \> 2mg/dL * INR\> 1.4 * ALT and AST \> 5 times UNL * Diffuse HCC defined as \>50% tumour involvement of the whole liver.